Which patients with resectable Stage IB-IIIA NSCLC would most benefit from using neoadjuvant chemoimmunotherapy as per CheckMate 816?  

CheckMate 816 enrolled patients with EGFR/ALK wildtype stage IB (>/= 4cm) through IIIA NSCLC, with recent approval from FDA based on improved event-free survival endpoint as well as pathologic complete response rates seen with the combination chemoimmunotherapy compared with standard chemotherapy...